MARKET

QGEN

QGEN

Qiagen
NYSE

Real-time Quotes | Nasdaq Last Sale

45.27
+0.82
+1.84%
After Hours: 45.27 0 0.00% 16:03 05/20 EDT
OPEN
45.28
PREV CLOSE
44.45
HIGH
45.49
LOW
44.78
VOLUME
1.49M
TURNOVER
0
52 WEEK HIGH
58.00
52 WEEK LOW
41.32
MARKET CAP
10.30B
P/E (TTM)
19.45
1D
5D
1M
3M
1Y
5Y
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
HILDEN, Germany & GERMANTOWN, Md., May 19, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its recently launched, environmentally friendlier QIAwave nucleic-acid extraction kits have received the prestigious ACT Environme...
Business Wire · 1d ago
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
Investors are optimistic about QIAGEN (QGEN), owing to strong international growth and bullish guidance.
Zacks · 1d ago
QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio
The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.
Zacks · 2d ago
QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer
The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.
Zacks · 4d ago
Qiagen launches QIAstat-Dx Rise system for testing multiple pathogens from one sample
Qiagen (NYSE:QGEN) launched QIAstat-Dx Rise and enhancements to tests for the one-step molecular testing solution that provides results in about one hour. The Netherlands-based company said QIAstat-Dx Rise is a high-capacity version of
Seekingalpha · 4d ago
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
HILDEN, Germany & GERMANTOWN, Md., May 16, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx automated syndromic system – and enhancements to the menu of ...
Business Wire · 4d ago
What Type Of Shareholders Own The Most Number of Qiagen N.V. (NYSE:QGEN) Shares?
If you want to know who really controls Qiagen N.V. ( NYSE:QGEN ), then you'll have to look at the makeup of its share...
Simply Wall St. · 05/11 16:15
Qiagen acquires majority stake in BLIRT, recombinant enzymes manufacturer
Qiagen (NYSE:QGEN) signed agreements to acquire a 96% majority ownership stake in Gdansk, Poland-based BLIRT, manufacturer of recombinant enzymes for the life science industry. BLIRT develops, manufactures and commercializes standardized and customized
Seekingalpha · 05/11 14:51
More
No Data
Learn about the latest financial forecast of QGEN. Analyze the recent business situations of Qiagen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
21.43%Buy
64.29%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average QGEN stock price target is 55.72 with a high estimate of 72.00 and a low estimate of 47.50.
High72.00
Average55.72
Low47.50
Current 45.27
EPS
Actual
Estimate
0.200.400.600.80
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 429
Institutional Holdings: 139.32M
% Owned: 61.25%
Shares Outstanding: 227.45M
TypeInstitutionsShares
Increased
101
11.84M
New
41
1.89M
Decreased
90
9.70M
Sold Out
46
8.50M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Chairman - Supervisory/Independent Director
Lawrence Rosen
Chief Executive Officer/Managing Director/Executive Board
Thierry Bernard
Chief Financial Officer/Managing Director/Executive Board
Roland Sackers
Independent Director/Supervisory Board
Metin Colpan
Independent Director/Supervisory Board
Thomas Ebeling
Independent Director/Supervisory Board
Toralf Haag
Independent Director/Supervisory Board
Ross Levine
Independent Director/Supervisory Board
Elaine Mardis
Independent Director/Supervisory Board
Elizabeth Tallett
No Data
No Data
About QGEN
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Webull offers kinds of Qiagen NV stock information, including NYSE:QGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QGEN stock methods without spending real money on the virtual paper trading platform.